
Keywords: prostatic neoplasms; prostatectomy; phosphodiesterase 5 inhibitors; recurrenceBCR, biochemical recurrence; BMI, body mass index; ED, erectile dysfunction; PDE5, phosphodiesterase type 5; PDE5i, phosphodiesterase type 5 inhibitors; PSA, prostate specific a